Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade
Summary Immune checkpoint blockade has transformed cancer therapy, but durable benefit is limited to a subset of patients and can be accompanied by immune-related adverse events. This Review evaluates inhibitory receptor profiles as candidate biomarkers for predicting both antitumor benefit and immune toxicity. We exam...